Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Enterobiome Inc. has 1 pending office action in Biotechnology & Pharmaceuticals. The record shows 1 distinct examiner and 1 distinct art unit, concentrating the current examination activity in one channel. DURYEE, ALEXANDER MARSH is the busiest examiner, with 1 pending matter.
The narrow assignment pattern supports a focused biotechnology prosecution strategy. Counsel can develop one coherent response to the pending action and avoid reconciling positions across different art units. Particular care should be given to the relationship between technical disclosure and claim scope, so that any amendment addresses the examiner’s concern without creating unnecessary limitations.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DURYEE, ALEXANDER MARSH | 1 | 33.3% | +41.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18801049 | METHOD AND FORMULATION FOR TREATING RESPIRATORY DISEASES | DURYEE, ALEXANDER MARSH | 1657 | §102§103§112Other | Non-Final OA | — | Pending | Aug 12, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEnterobiome Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Alexander Marsh Duryee has the most, with 1 of Enterobiome Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
